Recro to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020

Rhea-AI Summary

Recro Pharma (Nasdaq: REPH) will report its third quarter 2020 financial results on November 9, 2020, at 8:00 a.m. ET. The management team will host a conference call and audio webcast to discuss these results and recent operational highlights. Investors can access the call by dialing (844) 243-4691 or (225) 283-0379 for international participants. Recro specializes in contract development and manufacturing for oral solid dose drug products and has launched a new Clinical Trials Materials and Logistics business to enhance its service offerings.

Positive

• Launch of Clinical Trials Materials and Logistics business.
• Integrated solutions for formulation and manufacturing of oral solid dose drug products.

Negative

• None.

Conference Call and Webcast Scheduled for Monday, November 9, 2020 at 8:00 a.m. ET

MALVERN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that it will report third quarter 2020 financial results on Monday, November 9, 2020. Recro’s management team will host a conference call and audio webcast at 8:00 a.m. ET on Monday, November 9, 2020 to discuss the financial results and recent operational highlights.

To access the conference call please dial (844) 243-4691(local) or (225) 283-0379 (international) at least 10 minutes prior to the start time and refer to conference ID 9677189. A live audio webcast of the call will be available under "Events" in the Investor section of the Company's website, www.recrocdmo.com. An archived webcast will be available on the Company's website approximately two hours after the event and will be available for 30 days.

About Recro

Recro is a contract development and manufacturing, or CDMO, business, with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, with its operations location in Gainesville, GA. Recro recently launched its Clinical Trials Materials and Logistics business, including preparation of double-blind clinical trial supplies and also offers specialized services dedicated to the development and GMP manufacturing of high potency products. The Company leverages its formulation expertise to develop and manufacture pharmaceutical products using its proprietary delivery technologies and other manufacturing services for commercial and development-stage partners who commercialize or plan to commercialize these products. For more information see www.recrocdmo.com.

Contacts

Investor Relations Contacts:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
Sam@argotpartners.com
Claudia@argotpartners.com

Recro
Ryan D. Lake
(484) 395-2436
rlake@recropharma.com

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
David.rosen@argotpartners.com

FAQ

When will Recro Pharma report its third quarter 2020 financial results?

Recro Pharma will report its third quarter 2020 financial results on November 9, 2020.

What can investors expect from the upcoming conference call on November 9, 2020?

Investors can expect a discussion of financial results and recent operational highlights during the conference call on November 9, 2020.

How can I access the Recro Pharma conference call?

To access the conference call, dial (844) 243-4691 for local or (225) 283-0379 for international calls, at least 10 minutes prior to the start.

What services does Recro Pharma offer?

Recro Pharma offers contract development and manufacturing services for oral solid dose drug products, including formulation and regulatory support.